Recent developments in clinical trials for bronchial asthma.
Bronchial asthma is a chronic inflammatory disorder of the airways. Currently available antiinflammatory treatments, represented by inhaled corticosteroids (ICS), are highly effective in controlling symptoms in the majority of patients, but their potential side effects have led to the use of adjunctive or alternative therapies and to the development of new therapies. Most of these new agents are aimed at inhibiting various components of allergic inflammation, with better safety profiles than ICS. They include inhibitors of phosphodiesterase 4, cytokine modulators, chemokine receptor antagonists and antisense oligonucleotides.